Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025
Globenewswire·2025-09-23 12:00
Core Points - Regen BioPharma, Inc. is presenting an update on its Orphan Drug application for HemaXellerate, aimed at treating aplastic anemia and potentially addressing chemotherapy side effects, which represents a multi-billion dollar market [1][2] - The Company is preparing to enter Clinical Phase I for HemaXellerate, which has already received FDA clearance [2] Company Overview - Regen BioPharma, Inc. is a publicly traded biotechnology company focused on immunology and immunotherapy, advancing novel technologies through pre-clinical and Phase I/II clinical trials [4] - The Company is currently concentrating on mRNA and small molecule therapies for cancer and autoimmune disorders [4]